Evidence map›Paper›PMID 38851922›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2024

Symptom phenotyping in people with cystic fibrosis during acute pulmonary exacerbations using machine-learning K-means clustering analysis.

Eliana R Gill, Christopher Dill, Christopher H Goss, Scott D Sagel, Michelle L Wright, Sharon D Horner, Julie A Zuñiga

Abstract read
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Symptom factors and their clinical correlates among adults with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eliana R GillDivision of Biobehavioral Nursing and Health Informatics, Department of Nursing, University of Washington, Seattle, WA, United States. Electronic address: ergill@uw.edu.
Christopher DillUniversity of Houston, Houston Texas, United States.
Christopher H GossDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, WA, United States; Division of Pulmonary and Sleep Medicine, Department of Pediatrics, University of Washington, Seattle, WA, United States; Seattle Children's Research Institute, Seattle, WA, United States.
Scott D SagelDepartment of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado, United States.
Michelle L WrightNational Institutes of Health, Bethesda, Maryland, United States.
Sharon D HornerThe University of Texas at Austin School of Nursing, Austin, Texas, United States.
Julie A ZuñigaThe University of Texas at Austin School of Nursing, Austin, Texas, United States.

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4M
Precision Health Intervention Methodology Training in Self-Management of Multiple Chronic ConditionsT32NR019035 · NINR · UNIVERSITY OF TEXAS AT AUSTIN · PI STUIFBERGEN, ALEXA · 2020 to 2024
$995k
NCATS NIH HHS UL1 TR002535NIDDK NIH HHS P30 DK089507NINR NIH HHS T32 NR019035
6 · The paper itself

Abstract

introductionPeople with cystic fibrosis (PwCF) experience frequent symptoms associated with chronic lung disease. A complication of CF is a pulmonary exacerbation (PEx), which is often preceded by an increase in symptoms and a decline in lung function. A symptom cluster is when two or more symptoms co-occur and are related; symptom clusters have contributed meaningful knowledge in other diseases. The purpose of this study is to discover symptom clustering patterns in PwCF during a PEx to illuminate symptom phenotypes and assess differences in recovery from PExs.

methodsThis study was a secondary, longitudinal analysis (N = 72). Participants at least 10 years of age and being treated with intravenous antibiotics for a CF PEx were enrolled in the United States. Symptoms were collected on treatment days 1-21 using the CF Respiratory Symptom Diary (CFRSD)-Chronic Respiratory Symptom Score (CRISS). K-means clustering was computed on day 1 symptom data to detect clustering patterns. Linear regression and multi-level growth models were performed.

resultsSymptoms significantly clustered based on severity: low symptom (LS)-phenotype (n = 42), high symptom (HS)-phenotype (n = 30). HS-phenotype had worse symptoms and CRISS scores (p< 0.01) than LS-phenotype. HS-phenotype was associated with spending 5 more nights in the hospital annually (p< 0.01) than LS-phenotype. HS-phenotype had worse symptoms over 21 days than LS-phenotype (p< 0.0001).

conclusionSymptoms significantly cluster on day 1 of a CF-PEx. PwCF with HS-phenotype spend more nights in the hospital and are less likely to experience the same resolution in symptoms by the end of PEx treatment than LS-phenotype.

Indexed as

Cystic FibrosisDisease ProgressionMachine LearningPhenotypeAdolescentAdultAnti-Bacterial AgentsChildCluster AnalysisFemaleHumansLongitudinal StudiesMaleSeverity of Illness IndexSymptom AssessmentUnited StatesAnti-Bacterial AgentsCystic fibrosisPulmonary diseasePulmonary exacerbationPulmonary exacerbation outcomesRespiratory diseaseRespiratory symptomsSymptomSymptom clusteringSymptom phenotypeSymptom phenotyping

Identifiers

PMID38851922
PMCPMC11624099

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.